2025 年 12 月,中国医药行业正经历着前所未有的变革与机遇。国家医保局刚刚发布的2025 年版医保药品目录新增 114 种药品,其中包含 50 种 1 类创新药,首版商业健康保险创新药品目录同步公布,涵盖 18 家企业的 19 款产品。与此同时,全球医药巨头在2025 年掀起了史无前例的并购浪潮,强生以 146 亿美元收购 Intra-Cellular、诺华以 120 亿美元收购 ...
Source Link2025 年 12 月,中国医药行业正经历着前所未有的变革与机遇。国家医保局刚刚发布的2025 年版医保药品目录新增 114 种药品,其中包含 50 种 1 类创新药,首版商业健康保险创新药品目录同步公布,涵盖 18 家企业的 19 款产品。与此同时,全球医药巨头在2025 年掀起了史无前例的并购浪潮,强生以 146 亿美元收购 Intra-Cellular、诺华以 120 亿美元收购 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.